Health Canada approves Eli Lilly's oral GLP-1 weight-loss pill Foundayo, after Australian TGA clearances

Health Canada approves Eli Lilly's oral GLP-1 weight-loss pill Foundayo, after Australian TGA clearances

Health Canada approved Eli Lilly’s oral GLP-1 medication Foundayo for obesity and weight-related health issues. The approval follows earlier clearances by Australia’s Therapeutic Goods Administration, which had already authorized the daily tablet for adults with type 2 diabetes and obesity, providing a new oral option alongside existing injectable treatments. The Therapeutic Goods Administration’s decisions were reported by multiple Australian health outlets, noting that Foundayo joins Novo Nordisk’s Wegovy tablet as a prescription-only GLP-1 therapy available to patients later in the year.

Acteurs

Therapeutic Goods Administration Foundayo Lilly Samantha Hocking National Association of Clinical Obesity Services Lilly Australia Dr Manny Simons

Lieux

Australia
Verdict global: Partiellement confirmé Confiance: 71% Affirmations: 4
Résumé

All four claims regarding Eli Lilly’s oral GLP-1 drug Foundayo were partially confirmed. The Therapeutic Goods Administration approved Foundayo for adults with type 2 diabetes and obesity in Australia. The approval introduces a second daily GLP-1 weight-loss pill to the Australian market alongside Novo Nordisk’s Wegovy tablet. Foundayo, or orforglipron, will be available for prescription in Australia within days. The drug provides a new daily tablet option for weight management and diabetes.

Connectez-vous ou abonnez-vous pour voir l'analyse complète avec les affirmations, les sources et la validation chronologique.

Cette section contient une vérification automatisée des affirmations à partir de sources externes et peut contenir des inexactitudes.

Articles

18 novembre 2026
2 au total
Health Canada approves new Eli Lilly GLP-1 pill for weight loss
Health Canada approves new Eli Lilly GLP-1 pill for weight loss

Global News • 18 nov. 21h12

Health Canada approved Eli Lilly’s daily oral GLP-1 medication Foundayo for obesity and weight-related health issues, with availability expected in pharmacies in January.

Crédibilité 88% Manip. 8% Centre
Foundayo approval a welcome addition to GLP-1 treatment options
Foundayo approval a welcome addition to GLP-1 treatment options

Diabetes Australia • 18 nov. 00h43

The Therapeutic Goods Administration has approved Foundayo, an oral GLP-1 receptor agonist, offering a daily tablet option for eligible adults with type 2 diabetes and obesity.

Crédibilité 92% Manip. 8% Centre
17 novembre 2026
2 au total
1 to hit Australian shelves within days
1 to hit Australian shelves within days

Royal Australian College of General Practitioners (RACGP) • 17 nov. 05h34

Eli Lilly's oral GLP-1 medication orforglipron, sold as Foundayo, has been approved by the Therapeutic Goods Administration and will be available for prescription within days, offering a new option for weight management and type-2 diabetes treatment.

Crédibilité 88% Manip. 8% Centre
TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained
TGA approves daily weight-loss pills in Australia: Wegovy and oral GLP-1s explained

Nine.com.au • 17 nov. 02h45

The Therapeutic Goods Administration has cleared Eli Lilly’s Foundayo for weight management and type 2 diabetes, adding to Novo Nordisk’s Wegovy tablet, with both drugs requiring prescriptions and expected to reach patients later this year.

Crédibilité 88% Manip. 8% Centre
16 novembre 2026
1 au total
TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use
TGA approves first-of-its-kind GLP-1 weight loss pill Foundayo for Australian use

7NEWS • 16 nov. 22h38

The Therapeutic Goods Administration has authorized the oral GLP-1 medication Foundayo, developed by Lilly, for weight loss and type 2 diabetes treatment, with availability expected within days.

Crédibilité 88% Manip. 12% Centre